-

Sanguina Announces U.S. FDA-Clearance for AnemoCheck Home

AnemoCheck Home is the only FDA-cleared home anemia test with instant results

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Today, Sanguina, Inc. (Sanguina), a leading biotech company, is pleased to announce the FDA clearance of AnemoCheck Home, the only FDA-cleared home hemoglobin test kit available in the United States. AnemoCheck Home is a groundbreaking test designed to empower individuals with anemia due to nutritional deficiency (iron deficiency anemia, vitamin B12 deficiency anemia, and folate deficiency anemia), sickle cell disease, and thalassemia to monitor their hemoglobin levels in the comfort of their own homes. The test is an in vitro diagnostic device and will be available by prescription only, ensuring appropriate medical oversight and guidance.

Sanguina is proud to introduce AnemoCheck Home as a game-changer for at-home anemia testing. With this FDA clearance, we are excited to provide people who have anemia with a convenient, accurate, and accessible tool.

Share

Anemia, a condition marked by a shortage of healthy red blood cells or hemoglobin, affects over 1.92 billion individuals worldwide. Acknowledging the pressing need for accessible and reliable testing, AnemoCheck Home is an innovative solution for detecting and monitoring anemia for those who need it most.

AnemoCheck Home allows users to obtain accurate hemoglobin level readings by conducting a simple fingerstick blood test. The user performs a finger stick, collects blood into a sample collection tube, and then connects the test cap with a test body. The user then shakes the test to mix the blood. After 2 minutes, the color correlates to a hemoglobin level on a color card. The test is disposable and does not require any additional equipment.

Erika Tyburski, CEO of Sanguina states: "Our team at Sanguina is proud to introduce AnemoCheck Home as a game-changer for at-home anemia testing. With this FDA clearance, we are excited to provide people who have anemia with a convenient, accurate, and accessible tool to monitor their hemoglobin levels at home.”

AnemoCheck Home leverages the latest advancements in healthcare technology, ensuring reliable and precise results to empower users to take control of their anemia management. The kit includes user-friendly instructions, and everything needed to perform the fingerstick test safely and efficiently.

To learn more about AnemoCheck Home, please visit our website at https://sanguina.com/anemocheckhome.

About Sanguina, Inc

Sanguina is a leading biotech company focused on advancing accessible digital and at-home health platforms for rapid home-based testing and disease management. Founded in 2019, Sanguina aims to empower individuals by providing innovative solutions for diagnosing, monitoring, and managing wellness and chronic conditions. We strive to bring easy-to-use and innovative medical devices and diagnostics to the fingertips of patients and healthcare professionals.

Contacts

Jessica Tackett
Director of Marketing
Sanguina Inc.
jessy.tackett@sanguina.com

Sanguina, Inc.


Release Versions

Contacts

Jessica Tackett
Director of Marketing
Sanguina Inc.
jessy.tackett@sanguina.com

Social Media Profiles
More News From Sanguina, Inc.

Sanguina Announces Ruby: The Evolution of AnemoCheck Mobile's Blood Health Platform

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Sanguina, a digital health company, announced today the launch of Ruby, a comprehensive rebrand and expansion of its AnemoCheck Mobile app. Ruby builds upon the company's patented fingernail selfie technology for blood health monitoring while introducing new features, including circulation analysis, wellness tracking, and personalized health insights. Ruby extends beyond AnemoCheck Mobile's original focus on anemia management. Using the same patented fin...

Sanguina Raises $2.8M in Series A Funding to Drive Innovation in Home-Based Testing and Wellness Management

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its $2.8m Series A funding round. Led by Veritus Holdings, the round saw participation from notable investors, including George Hornig of The Seed Lab and Stephen Ippolito of Veritus Holdings. The funding will be used to accelerate the development and expansion of Sanguina's innovative blood health manag...

Sanguina Announces AnemoCheck Premium Subscription for 50% More Accurate Results

ATLANTA--(BUSINESS WIRE)--Today Sanguina, Inc. (Sanguina), a wellness and diagnostic tool company with an emphasis on anemia screening, announces the AnemoCheck app Premium Subscription which offers users 50% more accurate results. AnemoCheck is the first non-invasive app that provides instant hemoglobin estimation through a ‘fingernail selfie’ (test). Over the past year Sanguina also conducted a study titled “Clinical and Real-World Evaluation of a ‘Fingernail Selfie’ Smartphone App For Non-In...
Back to Newsroom